Fig. 3: MCL-1 inhibition does not sensitize for cell death induction by sorafenib and TRAIL in Hep3B cells. | Cell Death & Disease

Fig. 3: MCL-1 inhibition does not sensitize for cell death induction by sorafenib and TRAIL in Hep3B cells.

From: BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Fig. 3

A No significant cell death was observed in Hep3B cells treated with TRAIL (50 ng/ml) or the MCL-1 inhibitor A-1210477 (10 µM) alone. Combined treatment of Hep3B cells with TRAIL and the MCL-1 inhibitor did not result in enhanced cell death. B Sorafenib alone or in combination with the MCL-1 inhibitor did not significantly reduce cell viability in Hep3B cells. C Hep3B cells are not sensitized for cell death by combined treatment of sorafenib and TRAIL, both in the presence or absence of the MCL-1 inhibitor. The figures represent the results of three independent experiments. N.s. non-significant.

Back to article page